New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
11:56 EDTQGENQIAGEN moves up after strong earnings and guidance, levels to watch
The shares are up over 6.5% after the company turned in an earnings beat and raised guidance. At the current price of $21.28, next resistance is at $21.90. A big area of resistance stretching back several year is at $23.83. That will be an important test if and when shares get closer to that objective. Looking back on a ten year monthly chart will make that evident. Support is currently at $20.27.
News For QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
16:14 EDTQGENQIAGEN announces agreement with CosmosID Inc.
QIAGEN announced new partnerships to "enhance the profile and expand the use of its market leading bioinformatics solutions for microbiome, metagenomics and other applications." The company said, "QIAGEN Bioinformatics signed an agreement with genomics big data company CosmosID Inc., to allow users of QIAGEN's CLC Genomics Workbench to access and integrate CosmosID's metagenomics analysis platform into their QIAGEN bioinformatics platform. CosmosID's platform allows users to identify and characterize microbial communities from whole genome shotgun data and to determine their relative abundance. The new plug-in expands the range of metagenomic and microbiome applications supported by QIAGEN's microbial genomics solution enabling researchers in fields such as infectious disease, animal health, agriculture, environmental and food safety to use shotgun metagenomics analysis for routine testing employing next-generation sequencing."
16:12 EDTQGENQIAGEN says 'on course' to achieve the 2016 goals
Subscribe for More Information
16:12 EDTQGENQIAGEN reports Q4 adjusted EPS 31c, consensus 32c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use